Is TriSalus Life Sciences, Inc. (TLSI) Overvalued?
We dive into why TriSalus Life Sciences, Inc. (TLSI) could be considered overvalued on 2026-08-17, based on AAII’s Value Score and Grade.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States. It offers Pressure-Enabled Drug Delivery (PEDD) infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial for treating locally advanced pancreatic cancer. The company is also developing nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and pancreatic cancer. It serves interventional radiologists, IR technicians, medical oncologists, nursing support, and value analysis committee staff. The company was founded in 2009 and is headquartered in Westminster, Colorado.
Commentary & Analysis
Why TriSalus Life Sciences, Inc.’s (TLSI) Stock Is Up 8.32%
As of Friday, August 07, TriSalus Life Sciences, Inc.’s TLSI share price has surged by 8.32%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why TriSalus Life Sciences, Inc.’s (TLSI) Stock Is Up 13.55%
As of Friday, August 07, TriSalus Life Sciences, Inc.’s TLSI share price has surged by 13.55%, which has investors questioning if this is right time to sell.Omar Beirat
Why TriSalus Life Sciences, Inc.’s (TLSI) Stock Is Down 6.32%
As of Friday, July 24, TriSalus Life Sciences, Inc.’s TLSI share price has dipped by 6.32%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why TriSalus Life Sciences, Inc.’s (TLSI) Stock Is Down 5.50%
As of Wednesday, July 08, TriSalus Life Sciences, Inc.’s TLSI share price has dipped by 5.50%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | TLSI | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $293.1 | $279.4 | 31% |
|
| Shares Out (Mil) | 58.3 | 54.3 | 51% |
|
| Institutional Ownership | 76.1% | 92.9% | 46% |
|
| Float (Mil) | 49.5 | 42.3 | 47% |
|
| Beta | 0.43 | 0.95 | 24% |
|
| Avg Daily Volume (000s) | 106 | 468 | 37% |
|
| Price Change (52-week) |
(5.0%) | 57.1% | 44% |
|
| Growth | TLSI | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 52.9% | 14.1% | 96% |
|
| Net Income (5yr) | (4.3%) | (10.1%) | 35% |
|
| EPS (5yr) | 15.0% | 15.4% | 56 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 48.3% | (15.6%) | 93% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | ($0.155) | ($0.326) | ($0.264) | |
| Month Ago EPS | na | na | na | |
| # Rev Up | 1 | 1 | 1 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | ($0.110) | ($0.450) | ($0.250) | |
| Year/Year Chg | (3.1%) | (82.3%) | (106.5%) | |
| Financials | TLSI | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $45 | $37 | 19% |
|
| Net Income (TTM) (Mil) | ($28) | ($43) | 21% |
|
| EPS (TTM) | ($1.145) | ($1.500) | 20% |
|
| Operating Cash Flow (TTM) (Mil) | ($23) | ($31) | 14% |
|
| Net Cash Flow (TTM) (Mil) | $19 | $2 | 62% |
|
| Long-Term Debt (Q1) (Mil) | $34 | $4 | 36% |
|
| Enterprise Value (Q1) (Mil) | $313 | $195 | 29% |
|
| Valuation | TLSI | Industry Median |
Percentile (All Stocks) |
|
| P/B | 43.27 | 2.74 | 98% |
|
| P/E | na | 19.6 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | TLSI | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 85.8% | 67.6% | 92% |
|
| Net Margin | (62.6%) | (73.5%) | 10% |
|
| ROA | (54.4%) | (47.8%) | 11% |
|
| ROE | 438.3% | (55.0%) | 99% |
|
| Liabilities to Assets | 89.5% | 29.8% | 85% |
|
| F-Score | 5 | 3 | 50% |
|
TriSalus Life Sciences, Inc. did not pass any screens on 9/9/2026.
